Add-On Spironolactone for Persistent Proteinuria After Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients With Diabetic Kidney Disease: A Retrospective Observational Study

Key Points

• Spironolactone significantly reduces proteinuria in patients with diabetic kidney disease.
• The study observed a decrease in protein levels over a specified duration after treatment with spironolactone.
• Retrospective observational study analyzing records of patients treated with SGLT2 inhibitors.
• These findings support the idea of spironolactone as a beneficial add-on therapy for managing diabetic kidney disease.